Yoseph Shaaltiel

V.P R&D at Protalix Biotherapeutics - Miami, FL, US

Yoseph Shaaltiel's Colleagues at Protalix Biotherapeutics
Mirela Jakoel

Chemistry & Raw Material QC Manager

Contact Mirela Jakoel

Zehavit Glants

Quality assurance operations

Contact Zehavit Glants

Dror Kaldes

Calibration & Analytical Equipment Team Leader

Contact Dror Kaldes

Yair Kirshner

Production Senior Director

Contact Yair Kirshner

Kobi Marom

Validation Team Leader

Contact Kobi Marom

View All Yoseph Shaaltiel's Colleagues
Yoseph Shaaltiel's Contact Details
HQ
+972 4-902-8100
Location
Company
Protalix Biotherapeutics
Yoseph Shaaltiel's Company Details
Protalix Biotherapeutics logo, Protalix Biotherapeutics contact details

Protalix Biotherapeutics

Miami, FL, US • 250 - 499 Employees
BioTech/Drugs

Protalix (NYSE American, TASE: PLX) is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Protalix was the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix’s unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix’s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human α Galactosidase A protein for the treatment of Fabry disease; alidornase alfa or PRX 110, for the treatment of various human respiratory diseases or conditions; PRX 115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX 119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.

Protalix Protalix Biotherapeutics Protalix Biotherapeutics News Plx
Details about Protalix Biotherapeutics
Frequently Asked Questions about Yoseph Shaaltiel
Yoseph Shaaltiel currently works for Protalix Biotherapeutics.
Yoseph Shaaltiel's role at Protalix Biotherapeutics is V.P R&D.
Yoseph Shaaltiel's email address is ***@protalix.com. To view Yoseph Shaaltiel's full email address, please signup to ConnectPlex.
Yoseph Shaaltiel works in the BioTech/Drugs industry.
Yoseph Shaaltiel's colleagues at Protalix Biotherapeutics are Zohar Keren, Mirela Jakoel, Zehavit Glants, Dror Kaldes, Yair Kirshner, Sheli Levy, Kobi Marom and others.
Yoseph Shaaltiel's phone number is +972 4-902-8100
See more information about Yoseph Shaaltiel